Bio Pharmaceutical Pass-Through Chamber - Stainless Steel

| February 18, 2015

article image
The CleanSeam+ Pass-Through chamber isolates the interlock in a double-wall housing, providing the optimal transfer chamber for the broadest range of critical applications, including cleanliness requirements to ISO 4 and bio/pharmaceutical operations that require frequent cleaning and sterilization. Flush-mount design eliminates surfaces that collect contaminants, and double-wall constructions isolates interlock outside the transfer chamber. These features make this unit ideal for critical applications that require ultra-smooth, easy-clean surfaces.

Spotlight

PCI Biotech Holding ASA

PCI Biotech is a publicly listed Norwegian biotechnology company with a unique technology to improve localised treatment of cancer. The company has a focused and competent organisation localised at Lysaker just outside Oslo, Norway, with extensive collaboration with international experts and service providers. Clinical development of the lead product started in 2009 and has so far shown very promising results in localised treatment of head & neck cancer. The company has started a Phase II study in head & neck cancer, and is preparing for a phase I/II study in bile duct cancer to start by end of 1H 2013.

OTHER ARTICLES

5 Biotech Stocks Winning the Coronavirus Race

Article | April 13, 2020

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More

Defense biotech research looks to eliminate bacteria causing traveler’s diarrhea, reduce jet lag duration

Article | April 9, 2020

World traveler‘s will rejoice at the idea of a seemingly magical device that would guarantee they never suffer from the all-too-familiar stomach issues that come from traveling internationally while reducing jet lag at the same time. But it’s not just privileged globetrotters that would benefit from a device that eliminates the bacteria associated with the so-called Montezuma’s Revenge. In 2016, more than 230,000 children around the world died from some of the same types of bacteria as those that cause traveler’s diarrhea, and the bacteria mainly come from unsafe “drinking water, poor sanitation and malnutrition,” according to Oxford University’s Our World In Data portal. On Monday, DARPA announced it was researching an “implantable or ingestible bioelectronic carrier” that would eliminate the five major bacteria associated with traveler’s diarrhea.

Read More

Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020

Article | February 24, 2020

The year 2020 marks a decade since the term pharmacomicrobiomics was coined (Rizkallah et al., 2010) to crystallize a century-old concept of mutual interactions between humans, drugs, and the microbial world. The human microbiome, with its immense metabolic potential that exceeds and expands the human metabolic capacities, has the ability to modulate pharmacotherapy by affecting both pharmacokinetics and pharmacodynamics of drug molecules:

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

PCI Biotech Holding ASA

PCI Biotech is a publicly listed Norwegian biotechnology company with a unique technology to improve localised treatment of cancer. The company has a focused and competent organisation localised at Lysaker just outside Oslo, Norway, with extensive collaboration with international experts and service providers. Clinical development of the lead product started in 2009 and has so far shown very promising results in localised treatment of head & neck cancer. The company has started a Phase II study in head & neck cancer, and is preparing for a phase I/II study in bile duct cancer to start by end of 1H 2013.

Events